Portal de Periódicos da CAPES

Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients

2017; Elsevier BV; Volume: 76; Issue: 2 Linguagem: Inglês

10.1016/j.jinf.2017.11.008

1532-2742

Nathalie Satta, Sabrina Pagano, Fabrizio Montecucco, Bariş Gencer, François Mach, Laurent Kaiser, Alexandra Calmy, Nicolas Vuilleumier, Vincent Aubert, Julia M. I. Barth, Manuel Battegay, Enos Bernasconi, J Böni, H C Bucher, Claudine Burton‐Jeangros, Alexandra Calmy, Matthias Cavassini, Matthias Egger, Luigia Elzi, Jan Fehr, Jacques Fellay, P Francioli, Hansjakob Furrer, Christoph A. Fux, Meri Gorgievski, Huldrych F. Günthard, David Haerry, Barbara Hasse, Hans H. Hirsch, Bernard Hirschel, Irène Hösli, Christian R. Kahlert, Laurent Kaiser, Olivia Keiser, Christian Kind, Thomas Klimkait, Helen Kovari, Bruno Ledergerber, G Martinetti, Begoña Martínez de Tejada, Karin J. Metzner, Nicolas Müller, David Nadal, G Pantaleo, Andri Rauch, Stephan Regenass, Martin Rickenbach, Christoph Rudin, Patrick Schmid, D. Schultze, F. Schöni-Affolter, Jörg Schüpbach, Roberto F. Speck, Patrick Taffé, Philip Tarr, A. Telenti, Alexandra Trkola, Pietro Vernazza, Roger Weber, Sabine Yerly,

Systemic Lupus Erythematosus Research

Objectives To determine the existence of autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) in HIV patients and explore their association with biological features of HIV infection and different inflammatory biomarkers. We also evaluated their impact on CD4+ lymphocytes survival. Methods Anti-apoA-1 IgG plasma levels were assessed by ELISA in 237 HIV positive patients from a national prospective cohort with no current lipid-lowering therapy. Results 58% of patients were found positive for anti-apoA-1 IgG and were associated with lower CD4+ counts, but higher viremia and systemic inflammation. Logistic regression analyses indicated that high anti-apoA-1 IgG levels were associated with a 16-fold increased risk of displaying low CD4+ levels, independent of HIV RNA levels and treatment (adjusted Odds ratio [OR]:16.1, 95% Confidence Interval [95%CI]:1.80–143.6; p = 0.01), and a 6-fold increased risk of having a detectable viremia, independent of antiretroviral treatment (OR:5.47; 95% CI:1.63–18.36; p = 0.006). In vitro, anti-apoA-1 IgG induced dose and time-dependent CD4+ apoptosis that was increased by exposure to HIV RNA. Conclusions In HIV patients, anti-apoA-1 IgG levels are associated with low CD4+ counts, high viremia and a pro-inflammatory systemic profile. Anti-apoA-1 IgG can promote CD4+ lymphocyte apoptosis via undefined pathways.